title: Quinolines: a new hope against inflammation.
abstract: Although a number of anti-inflammatory drugs have been discovered and developed to treat diseases associated with acute and chronic inflammation, many anti-inflammatories cause adverse side effects. The quinoline framework has emerged as a new template for the design and identification of novel anti-inflammatory agents. These agents are classified based on the number of substituents present on the quinoline ring or compounds containing a quinoline ring fused to other heterocycles. This review focuses on the discovery of various quinoline derivatives as inhibitors of cyclooxygenase (COX), phosphodiesterase 4 (PDE4) and tumour necrosis factor-α converting enzyme (TACE), along with transient receptor potential vanilloid 1 (TRPV1) antagonists.
authors.affiliation: Organic and Medicinal Chemistry, Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500046, India.
authors.forename: Soumita
authors.initials: S
authors.lastname: Mukherjee
authors.forename: Manojit
authors.initials: M
authors.lastname: Pal
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D052246:Cyclooxygenase 2 Inhibitors; D016207:Cytokines; D010726:Phosphodiesterase Inhibitors; D011804:Quinolines; D050916:TRPV Cation Channels